Pharmexa says Padre data confirm versatility of Alzheimer's vaccine

By Elaine Rigoli

Tampa, Fla., Aug. 25 - Pharmexa a/s said Friday that a group of U.S. scientists has tested the company's Padre epitope in a prototype Alzheimer's vaccine, confirming the versatility of the Padre epitope across a broad range of applications.

The prototype vaccine, a combination of a fragment of the Abeta peptide and Pharmexa's Padre epitope, gave rise to high anti-Abeta antibody titers in vaccinated mice.

No unwanted cellular immune responses were detected, and there were no signs of side effects in the brains of the animals, according to a news release.

The company said this data confirms Pharmexa's hypotheses that a safe and effective Alzheimer's vaccine may be developed using dominant helper cell epitopes such as Padre that will alleviate the side effects observed with earlier Abeta vaccines.

Based in Horsholm, Denmark, Pharmexa develops immunotherapy and vaccines for the treatment of cancer, serious chronic diseases and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.